Maiwei Biology: Net Loss of 551 million yuan in the first half of 2025.

Maiwei Biotechnology announced that the operating income in the first half of 2025 was 101 million yuan, a year-on-year decrease of 12.43%. The net loss attributable to the shareholders of the listed company was 551 million yuan, compared to a net loss of 445 million yuan in the same period last year.